MODIFICATION
66 -- COTS for Multiplexed Biodetection System
- Notice Date
- 8/31/2010
- Notice Type
- Modification/Amendment
- NAICS
- 334519
— Other Measuring and Controlling Device Manufacturing
- Contracting Office
- Department of Energy, Pacific Northwest National Laboratory - Battelle (DOE Contractor), PNNL Contracts, PO Box 999, Richland, Washington, 99352
- ZIP Code
- 99352
- Solicitation Number
- RFI08032010
- Archive Date
- 10/2/2010
- Point of Contact
- Jennifer Miles-Ecclestone, Phone: 5093754467, Jennifer Miles-Ecclestone, Phone: 5093754467
- E-Mail Address
-
rfi.cots.mdb@pnl.gov, rfi.cots.mdb@pnl.gov
(rfi.cots.mdb@pnl.gov, rfi.cots.mdb@pnl.gov)
- Small Business Set-Aside
- N/A
- Description
- Request for Information (RFI) COTS for Multiplexed Biodetection Systems Introduction Battelle Memorial Institute, Pacific Northwest Division in operation of the Pacific Northwest National Laboratory (PNNL) for the U.S. Department of Energy is requesting information, seeking sources, and conducting market research. The purpose of this RFI is to identify potential vendors who have commercial off the shelf (COTS) instrumentation capable of multiplexed biological detection from environmental samples that can meet the requirements as outlined below. Responses to this RFI are solely for the purpose of market research. Nothing in this RFI shall be interpreted as a commitment on the part of PNNL to enter a contract with any respondent or to make any procurement. Responses will serve to assist PNNL in identifying the number and nature of the entities that comprise the universe of feasible technical solution providers for multiplexed biodetection to meet Government needs. Each respondent, by submitting a response to this RFI, agrees that any cost incurred in responding to this request, or in support of activities associated with this RFI, shall be the sole responsibility of respondent. PNNL shall incur no obligations or liabilities whatsoever, to anyone, for any costs or expenses incurred by the respondent in responding to this RFI. Section I: Requirements for Multiplexed Biological Detection Platforms General guidelines: A detection platform is sought that is capable of detecting at least 40 distinct nucleic acid signatures (signatures are defined as unique sequence islands that serve to help identify bioorganisms) for pathogen detection. Additional performance guidelines are summarized below, and the respondents should discuss the instrument performance relative to these guidelines. We are interested in instruments that meet/exceed the performance guidelines or come close to achieving these guidelines. In cases where the guidelines are not currently met, discuss how they could be met in the future. Furthermore, it is assumed that there will be separate equipment for air collection and sample preparation that will not be part of this COTS technology evaluation, therefore, we do not require platforms which perform these functions. Platforms that do perform these functions (e.g. air filtration and/or sample processing for nucleic acid analysis) must have the capability to receive previously processed samples for nucleic acid analysis. Price of Instrumentation: PNNL is interested in instruments that retail less than $250,000.00 USD. Time to detect: The total time for detection from samples ready for nucleic acid analysis (after collection and sample processing), should be less than or equal to 8 hrs. The detection platform should also be automated after sample input and provide automated results that can easily be interpreted within 8 hrs. Multiplexing: A minimum of 40 distinct assays (e.g., 2 distinct assays each for 20 organisms) per sample is desired. Multiplexing can be achieved by "single tube analysis" (e.g. a true multiplexed PCR, or community amplification) or a single sample can be split for multiple separate reactions. In the latter case where a sample is split, the minimum detection limit will change as described below. Molecules of interest: The platform should be able to detect both DNA and RNA. The platform should include all processing steps needed for DNA or RNA analysis (from a purified nucleic acid sample). Limit of detection (LOD): If multiplexing is achieved in a single sample reaction then the platform should achieve a limit of detection of < 500 genome copies per organism/virus in the original input sample. If multiplexing is achieved by splitting the sample into multiple separate reactions then each reaction should detect at least 500/(# of reactions) genome copies. For example if 50 separate reactions are performed then each reaction must be able to detect < 10 genomic copies per gene of interest. Cross-reactivity: Assays for the multiplexed detection platform should not cross-react with near-neighbor species or strains. The target non-detection limit is > 100,000 genome copies per input sample regardless of whether the platform operates using a single tube multiplex vs. a multichannel detection mode. Interference testing: With near neighbors Target organisms must meet LOD in the presence of > 100,000 copies of near neighbor species or strains per input sample. The 100,000 genome copy per input sample limit applies to both single tube and multiple channel platforms. With environmental samples Target organisms must meet LOD in the presence of 1 ng of total nucleic acid (per input sample) isolated from appropriate environmental samples. These environmental samples could be harvested from soils, air filter units, or water samples. Other considerations: It is understood that COTS platforms currently on the market may not have assays that are suitable for the biological agents (bacteria and viruses) of our interest. In responses to this RFI, vendors should state the general method and timeline of assay development for their platform and the multiplexing capability, sensitivity, specificity, and known interferents of their existing assays. Section II: Responding to this RFI If your company has a commercial off the shelf biodetection platform that can potentially meet the requirements outlined in Section I, please provide the information listed below. Respondents who best meet the stated requirements may be contacted regarding participation in a future wet-bench evaluation study. Identifying Information and Qualifications (Required): 1. Company Name/Division 2. Single point-of-contact name, title, telephone, and email address 3. Fair market price and/or GSA pricing 4. Small business qualification status 5. Country where business is owned and operated 6. Please provide answers to this short survey. a. Does your detection platform cost less than USD $250,000? (yes/no) b. What is the detection time for your platform (from sample addition to answer)? c. Is your platform automated such that a sample ready for detection can be input into the instrument and provide analyzed results for easy interpretation? (yes/no) d. How many nucleic acid assays can your system complete within the detection time for your platform? e. Can your instrument detect both DNA and RNA (yes/no)? If not, could your system be easily modified to detect both DNA and RNA? f. What is the limit of detection of your platform (this is the limit of detection with multiplexing of 40 or more assays)? How is this measured? g. Has cross reactivity been tested with near-neighbors? (yes/no) h. Has cross-reactivity been tested with environmental samples (e.g., soil, water, air filters)? (yes/no) i. Has the instrument been tested by loading the system with high concentrations of interfering DNA/RNA? (yes/no) 7. Based on the responses from the survey above, develop a white paper of no more than 5 pages elaborating on your answers, and further addressing: a. Fundamental principles and technologies used in the platform. b. The maturity and extent of use of the technology. c. System level test results, particularly those conducted by independent "third party" test organizations; test results should be attached to the RFI response (not included in the 5 page limit). d. Any peer-reviewed publications (not included in the 5 page limit) documenting the performance of the detection system should also be attached to the RFI response. e. If the biodetection technology has been used in an operational environment, provide a summary of each use, including the user, length of time in service, and relevant performance information (performance reports should be attached, and are not included in the 5 page limit). f. List or summarize the nucleic acid assays already developed for the platform, as well as an estimation of the effort for the development of additional assays using the detection platform. g. Indicate SAFETY Act certification status, if applicable. Section III. Submission details and questions 1. Responses are limited to five (5) pages; font size shall be no less than 12 points (10 points for figures and tables). Attachments (test reports, product brochures, publications) may be submitted, and will not be included in the page limit. 2. Please provide any other information you believe to be important and germane to the purposes of this Request for Information. 3. Proprietary information submitted as part of the response to the RFI must be clearly identified and marked as PROPRIETARY. 4. Potential respondents may submit questions regarding this RFI to the contacts listed below. Responses to questions received on or before August 20, 2010. PNNL may consider questions received after that date, but there is no obligation for PNNL to post any further answers. Contact: Jennifer Miles-Ecclestone, Senior Contracts Specialist at the following email address: rfi.cots.mdb@pnl.gov PNNL will only give consideration to submissions in response to this notice that are in the form of Microsoft Word documents attached to emails received no later than September 17, 2010 addressed to Jennifer Miles-Ecclestone, Senior Contracts Specialist, at the following email address: rfi.cots.mdb@pnl.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DOE/PNNL/PN/RFI08032010/listing.html)
- Place of Performance
- Address: see RFI, Richland, Washington, 99354, United States
- Zip Code: 99354
- Zip Code: 99354
- Record
- SN02261247-W 20100902/100831235036-05158a77da7488c47bb23d1e270c7def (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |